Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
15.23
-0.30 (-1.93%)
Sep 3, 2026, 12:14 PM EDT - Market open
Design Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 12.91 | 16.86 | 22.56 | 21.2 | 26.5 | 298.57 |
Short-Term Investments | 194.49 | 202.99 | 222.91 | 260.6 | 303.89 | 85.5 |
Cash & Short-Term Investments | 207.4 | 219.85 | 245.48 | 281.8 | 330.39 | 384.06 |
Cash Growth | -4.11% | -10.44% | -12.89% | -14.71% | -13.98% | 964.15% |
Other Receivables | 1.79 | 1.68 | 1.26 | 1.43 | 1.12 | 0.11 |
Receivables | 1.79 | 1.68 | 1.26 | 1.43 | 1.12 | 0.11 |
Prepaid Expenses | 2.83 | 2.26 | 1.3 | 1.35 | 3.62 | 1.26 |
Total Current Assets | 212.01 | 223.78 | 248.04 | 284.58 | 335.12 | 385.44 |
Property, Plant & Equipment | 3.12 | 2.42 | 3.63 | 4.63 | 5.56 | 5.12 |
Other Long-Term Assets | - | - | 0.43 | 0.43 | 0.46 | - |
Total Assets | 215.13 | 226.2 | 252.09 | 289.64 | 341.14 | 390.56 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.14 | 2.31 | 2.19 | 1.94 | 3.03 | 1.62 |
Accrued Expenses | 7.47 | 9.85 | 5.48 | 6.97 | 7.11 | 3.17 |
Current Portion of Leases | 0.63 | 0.89 | 0.8 | 0.72 | 0.64 | 0.49 |
Total Current Liabilities | 11.24 | 13.06 | 8.46 | 9.62 | 10.78 | 5.28 |
Long-Term Leases | 2.03 | 0.65 | 1.53 | 2.33 | 3.05 | 3.14 |
Total Liabilities | 13.27 | 13.7 | 10 | 11.96 | 13.83 | 8.43 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 537.43 | 509.1 | 468.83 | 455.25 | 441.42 | 429.82 |
Retained Earnings | -334.81 | -297.01 | -227.21 | -177.63 | -110.76 | -47.46 |
Comprehensive Income & Other | -0.77 | 0.4 | 0.48 | 0.06 | -3.36 | -0.24 |
Total Common Equity | 201.86 | 212.5 | 242.1 | 277.69 | 327.31 | 382.13 |
Shareholders' Equity | 201.86 | 212.5 | 242.1 | 277.69 | 327.31 | 382.13 |
Total Liabilities & Equity | 215.13 | 226.2 | 252.09 | 289.64 | 341.14 | 390.56 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.66 | 1.54 | 2.33 | 3.05 | 3.69 | 3.63 |
Net Cash (Debt) | 204.73 | 218.31 | 243.14 | 278.75 | 326.7 | 380.43 |
Net Cash Growth | -4.48% | -10.21% | -12.77% | -14.68% | -14.12% | 954.09% |
Net Cash Per Share | 3.42 | 3.81 | 4.30 | 4.98 | 5.86 | 8.28 |
Filing Date Shares Outstanding | 62.58 | 61.67 | 56.76 | 56.49 | 55.9 | 55.46 |
Total Common Shares Outstanding | 62.58 | 60.4 | 56.75 | 56.47 | 55.9 | 55.44 |
Working Capital | 200.77 | 210.73 | 239.58 | 274.96 | 324.34 | 380.15 |
Book Value Per Share | 3.23 | 3.52 | 4.27 | 4.92 | 5.86 | 6.89 |
Tangible Book Value | 201.86 | 212.5 | 242.1 | 277.69 | 327.31 | 382.13 |
Tangible Book Value Per Share | 3.23 | 3.52 | 4.27 | 4.92 | 5.86 | 6.89 |
Machinery | 3.09 | 3.07 | 2.91 | 2.6 | 2.32 | 1.54 |
Construction In Progress | - | - | - | - | - | 0.01 |
Leasehold Improvements | 0.17 | 0.17 | 0.15 | 0.15 | 0.15 | 0.1 |